Sandoz Group (SDZNY) Stock Price, News & Analysis

Company Overview

Sandoz Group AG is a Switzerland-based pharmaceutical company focused on developing, manufacturing and marketing generic and biosimilar medicines. Its portfolio is designed to expand access to established treatments by offering alternatives to branded products after patent or regulatory exclusivity periods end.

The company supplies medicines across a range of therapeutic areas, including anti-infectives, ophthalmology, respiratory care, central nervous system treatments, dermatology, transplantation and immunology. Sandoz also develops biosimilars, which are highly similar versions of biologic medicines, alongside traditional small-molecule generics.

Sandoz traces its origins to a chemical company established in Basel in 1886 and operated for many years as the generics division of Novartis. It became an independent, publicly traded company in October 2023 following its spin-off from Novartis. Headquartered in Basel, Switzerland, Sandoz serves patients and healthcare providers in more than 100 countries, with operations spanning Europe, North America and emerging markets. The company is led by Chief Executive Officer Richard Saynor.

Key Stats

• Today's Range: $87.30 to $87.92
• 50-Day Range: $79.75 to $93.01
• 52-Week Range: $60.40 to $94.15
• Volume: 13,297 shs
• Average Volume: 29,109 shs
• Market Capitalization: $38.68 billion
• P/E Ratio: N/A
• Dividend Yield: 0.69%
• Price Target: N/A
• Consensus Rating: Strong Buy

Sandoz Group Stock Analysis - MarketRank™

Sandoz Group scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Sandoz Group has received a consensus rating of Strong Buy. The company's average rating score is 3.60, and is based on 4 strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Sandoz Group has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 11.81%

Earnings Growth

Earnings for Sandoz Group are expected to grow by 11.81% in the coming year, from $4.15 to $4.64 per share.

Price to Earnings Growth Ratio

Sandoz Group has a PEG Ratio of 1.69. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Sandoz Group has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Sandoz Group has been sold short.

Short Interest Ratio / Days to Cover

Sandoz Group has a short interest ratio ("days to cover") of 2.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sandoz Group has recently increased by 9.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Sandoz Group has a dividend yield of 0.72%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sandoz Group does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Sandoz Group will have a dividend payout ratio of 13.15% next year. This indicates that Sandoz Group will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.20

News Sentiment

Sandoz Group has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Sandoz Group this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for SDZNY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sandoz Group insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.05% of the stock of Sandoz Group is held by institutions.

Company Calendar

• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:SDZNY
• CIK: 1992829
• Web: www.sandoz.com
• Phone: 41-61-324-11-11
• Fax: N/A
• Employees: 23,567
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 21.19
• P/E Growth: 1.69
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $11.09 billion
• Price / Sales: 3.49
• Cash Flow: $3.74 per share
• Price / Cash Flow: 23.52
• Book Value: $21.33 per share
• Price / Book: 4.12

Miscellaneous

• Outstanding Shares: 440,000,000
• Free Float: N/A
• Market Cap: $38.68 billion
• Optionable: Not Optionable
• Beta: 0.58